使用双膦酸盐后子宫内膜癌和卵巢癌风险降低的荟萃分析
该荟萃分析检索MEDLINE、EMBASE和Web of Science至2017年1月,纳入7项研究,评估使用双膦酸盐后子宫内膜癌和卵巢癌风险变化。结果显示任何双膦酸盐使用与子宫内膜癌风险显著降低27%相关(RR=0.73,95%CI:0.58-0.93,P=0.012),但卵巢癌风险降低不显著(RR=0.81,95%CI:0.58-1.14,P=0.227)。
要点
- 任何双膦酸盐使用与子宫内膜癌风险显著降低27%相关(RR=0.73,95%CI:0.58-0.93,P=0.012)。
- 双膦酸盐使用与卵巢癌风险降低无显著关联(RR=0.81,95%CI:0.58-1.14,P=0.227)。
- 子宫内膜癌保护效应主要见于绝经后女性或使用超过1年者。
核心结论
- 该荟萃分析提示,使用双膦酸盐与子宫内膜癌风险降低相关,但与卵巢癌风险降低无关。
研究设计与样本
- 荟萃分析,检索MEDLINE、EMBASE和Web of Science数据库至2017年1月。
- 共纳入7项研究,合计6471例子宫内膜癌病例(7项研究,213920名参与者)和6783例卵巢癌病例(4项研究,105507名参与者)。
- 采用随机效应模型计算汇总相对危险度(RR)。
主要发现
- 任何双膦酸盐使用与子宫内膜癌风险显著降低27%相关(RR=0.73,95%CI:0.58-0.93,P=0.012)。
- 双膦酸盐使用与卵巢癌风险降低无显著关联(RR=0.81,95%CI:0.58-1.14,P=0.227)。
- 在绝经后女性中,双膦酸盐使用与子宫内膜癌风险降低相关(RR=0.53,95%CI:0.34-0.93,P=0.012)。
- 在使用双膦酸盐超过1年的女性中,子宫内膜癌风险降低相关(RR=0.57,95%CI:0.35-0.93,P=0.024)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Recent epidemiological studies have investigated the associations between the use of bisphosphonates and the development of endometrial cancer and ovarian cancer; these studies have shown controversial results. Hence, this meta-analysis was conducted to evaluate the changes in the risks of developing endometrial and ovarian cancers after using bisphosphonates based on current evidence. METHODS: A comprehensive search was performed in the MEDLINE, EMBASE, and Web of Science databases through January 2017. The summary relative risk (RR) estimates for the effects of the use of bisphosphonates on the risks of developing endometrial and ovarian cancers were calculated using a random-effects model. RESULTS: Seven studies were included with a total of 6471 endometrial cancer cases (7 studies with 213,920 participants) and 6783 ovarian cancer cases (4 studies with 105,507 participants). This meta-analysis suggested that any use of bisphosphonates was associated with a significant 27% reduction in the risk of endometrial cancer (RR = 0.73, 95% CI: 0.58-0.93, P = 0.012), but the reduction in the risk of ovarian cancer (RR = 0.81, 95% CI: 0.58-1.14, P = 0.227) was not significant. The protective effects of the use of bisphosphonates against endometrial cancer are mainly found in postmenopausal women (RR = 0.53, 95% CI: 0.34-0.93, P = 0.012) or in those who have taken bisphosphonates for longer than 1 year (RR = 0.57, 95% CI: 0.35-0.93, P = 0.024). CONCLUSION: This meta-analysis suggests that the use of bisphosphonates is associated with a reduction in the risk of endometrial cancer but not ovarian cancer.
引用
- Zhang XS, Zhang YM, Li B, et al. Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis. Gynecol Oncol. 2018. PMID: 29960711. doi:10.1016/j.ygyno.2018.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。